glp-1 weight loss drugs list Market Overview: Agonists and the Obesity Market | Blog List of approved and pending

doi: 10.1503/cmaj.101281 Summary Keywords sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, type 2 diabetes, metformin, meta-analysis Citation Deng R, Mei K, Song T, Huang J, Wu Y, Yu P, Yan Z and Liu X (2024) First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis

Synthetic incretin receptor agonists are similar to natural incretins and can mimic their effect

Primary objectives for pharmaceutical weight loss should focus on optimizing diet composition and nutrient intake in addition to managing side effects

Maintenance: 0.5 - 2 mg SQ once weekly Max: 2 mg SQ once weekly Dose may be increased to 1 mg and then 2 mg if necessary